Project Name：And imatinib mesylate capsules, tablets 

Registration Classification：3+6

Formulations and specifications ：Capsules: 0.1g, tablets: 0.1g, 0.4g. 

Indications：For the treatment of chronic myeloid leukemia (CML) blast phase , accelerated phase or chronic phase after failure of α- interferon therapy ; also for the unresectable or metastasis malignant gastrointestinal stromal tumors (GIST) .

Original Research Company：Novartis (Novartis). 

Progress ：Completed Process Research